Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Screening and Mechanism of Trapping Ligand Antagonist Peptide for Chemokine Receptor US28 of Human Cytomegalovirus

Hongai Liu, Hanxiao Sun , Lu Li, Xuemei Mo, Xiuying Li, Guang Zhang

Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China;

For correspondence:-  Hanxiao Sun   Email: sunhx718@yahoo.com.cn   Tel:+8602038375022

Received: 7 November 2011        Accepted: 22 March 2012        Published: 24 April 2012

Citation: Liu H, Sun H, Li L, Mo X, Li X, Zhang G. Screening and Mechanism of Trapping Ligand Antagonist Peptide for Chemokine Receptor US28 of Human Cytomegalovirus. Trop J Pharm Res 2012; 11(2):193-200 doi: 10.4314/tjpr.v11i2.4

© 2012 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: The aim of the present study was to develop peptide H9 as an efficient antagonist of human cytomegalovirus (HCMV) chemokine receptor US28.
Methods: US28 gene was amplified from HCMV, and a stable expression system was constructed using NIH/3T3 cells. Interaction between peptide H9 and receptor US28 was tested by enzyme-linked immunosorbent assay. Flow cytometry was used to determine intracellular concentrations of Ca2+, and the possible role of H9 as an antagonist was evaluated by anti-viral experiments.
Results: H9 interacts with the US28 receptor and prevents an increase of Ca2+ resulting from an interaction of chemokine with its receptor. Anti-viral assays showed that H9 could inhibit cytopathic effects of HCMV. AD169 infection (EC50 = 0.46 ng/ml), and the production of pp65 antigen were strongly inhibited with an EC50 value of 0.34 ng/ml.
Conclusion: The results demonstrate that H9 is an antagonist of US28, suggesting a possible role as a treatment for HCMV.

Keywords: Human cytomegalovirus, US28, Peptide H9, Trapping receptor/ligand, Antagonist

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates